Voriconazole potentiates warfarin-induced prothrombin time prolongation

British Journal of Clinical Pharmacology, Supplement

Volumn 56, Issue 1, 2003, Pages 24-29

  Purkins, Lynn ^a   Wood, Nolan ^a   Kleinermans, Diane ^b   Nichols, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Drug interaction; Pharmacodynamics; Prothrombin; Voriconazole; Warfarin

Indexed keywords

CYTOCHROME P450; ISOENZYME; VORICONAZOLE; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; GINGIVA BLEEDING; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHOTOPHOBIA; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; VASODILATATION; VISUAL DISORDER;

EID: 0344943294     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01995.x     Document Type: Article

References (27)

1. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today 2001; 37: 135-148.
4. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 305, September 2000.
5. Perfect J, Gonzalez-Ruiz A, Lutsar I. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 303, September 2000.
6. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
7. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1: 176-182.
8. Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F78, September 1995.
9. Patterson BE, Roffey S, Jezequel SG, Jones B. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F79, September 1995.
10. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 21: 676-683.
11. Pemberton MN, Sloan P, Ariyaratnam S, Thakker NS, Thornhill MH. Derangement of warfarin anticoagulation by miconazole oral gel. Br Dent J 1998; 184: 68-69.
12. Black DJ, Kunze KL, Wienkers LC et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 4: 422-428.
13. Warwick JA, Corrall RJ. Serious interaction between warfarin and oral terbinafine. Br Med J 1998; 316: 440.
14. Gupta AK, Ross GS. Interaction between terbinafine and warfarin. Dermatology 1998; 196: 266-267.
15. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
16. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. New Engl J Med 1971; 285: 547-558.
17. Height and Weight Standards. New York, NY: Metropolitan Life Insurance Company, 1993.
18. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997; 691: 441-448.
19. SAS/STAT User's Guide, Version 6, 4th edn. Cary, NC: SAS Institute Inc., 1989.
20. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
21. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24: 414-421.
22. Takahashi H, Kashima T, Nomizo Y et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-528.
23. Lamba JK, Dhiman RK, Kohli KK. Genetic polymorphism of the hepatic cytochrome P450 2C19 in North Indian subjects. Clin Pharmacol Ther 1998; 63: 422-427.
24. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998; 20: 243-247.
25. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-niephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9: 539-549.
26. Tomaszewski K, Purkins L. Visual Effects with Voriconazole. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Abstract 639, September 2001.
27. Ally R, Schürmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Inject Dis 2001; 33: 1447-1454.